trial

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients

NCTId NCT07045142
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 400 (estimated)
Sponsored by Central South University
Primary completion 2027-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
400 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-07-01
Primary completion
2027-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AtorvastatinMetformin

Sponsors

Central South UniversityLead Sponsor
Zhumadian Second People's HospitalCollaborator
The Third Hospital of Changsha CountyCollaborator
The Second People's Hospital of Dali Bai Autonomous PrefectureCollaborator
Xiangshan County Traditional Chinese Medicine Hospital Medical and Health Group Three Hospitals DistricCollaborator
Yueyang Rehabilitation HospitalCollaborator
Junshan District Psychiatric Rehabilitation HospitalCollaborator
The Second People's Hospital of Xiangyin CountyCollaborator

Investigators

1
Renrong Wu, ProfStudy Chair

Sites

8 total
Zhumadian, ChinaChangsha, ChinaChangsha, ChinaYueyang, ChinaYueyang, ChinaYueyang, ChinaDali, ChinaXiangshan, China

Linked catalysts

1
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophr — primary completion2027-12-31

Facts & assertions

4 sourced
Enrollment
400
Phase
PHASE3
Primary Completion Date
2027-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Atorvastatin
drug
Metformin
drug
lead_sponsor
Central South University
company
collaborator
Zhumadian Second People's Hospital
company
The Third Hospital of Changsha County
company
indication
Schizophrenia
indication
Dyslipidemias
indication
Schizophrenia
indication
investigator
Renrong Wu, Prof
person